SCHEMBL16372385

SCHEMBL16372385

O=C(NC1=C(c2cccc(F)c2F)CC1)c1ccccc1C(F)(F)F

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 1/20 0.46
▸ GAA P10253 1/20 0.46
▸ PTPRC P08575 1/20 0.46
▸ KCNK3 O14649 3/20 0.45
▸ KCNK9 Q9NPC2 3/20 0.45
▸ PTGS1 P23219 1/20 0.45
▸ RXFP1 Q9HBX9 1/20 0.42
▸ F2R P25116 1/20 0.41
▸ PPIA P62937 1/20 0.41
▸ IDO1 P14902 2/20 0.41
▸ TP53 P04637 1/20 0.40
▸ RECQL P46063 1/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ MEN1 O00255 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ KAT6A Q92794 1/20 0.39
▸ GRM5 P41594 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16392354 0.83 PTPRC (0.48) LMNAGAAPTPRCKCNK3KCNK9
SCHEMBL16372428 0.77 KDM4E (0.51) LMNAGAAPTPRCKCNK3KCNK9
SCHEMBL16486751 0.76 LMNA (0.48) LMNAGAAPTPRCKCNK3KCNK9
SCHEMBL16371764 0.76 GAA (0.48) LMNAGAAPTPRCKCNK3KCNK9
SCHEMBL16371758 0.74 LMNA (0.55) LMNAGAAPTPRCKCNK3KCNK9
SCHEMBL16372308 0.74 LMNA (0.59) LMNAGAAPTPRCKCNK3KCNK9
SCHEMBL2937452 0.73 SMN1; SMN2 (0.56) LMNAGAAPTPRCKCNK3KCNK9
SCHEMBL16486057 0.71 KCNK3 (0.43) LMNAGAAPTPRCKCNK3KCNK9
SCHEMBL16512729 0.71 GRM4 (0.45) LMNAGAAKCNK3KCNK9PTGS1
SCHEMBL1825356 0.71 MEN1 (0.52) LMNAPTPRCKCNK3KCNK9PTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE50724-E1 4-membered ring carboxamides used as nematicides SYNGENTA CROP PROTECTION AG (CH) 2026-01-06 — — US disclosed
EP-3019476-B1 4-MEMBERED RING CARBOXAMIDES USED AS NEMATICIDES SYNGENTA PARTICIPATIONS AG (CH) 2018-01-17 — — EP disclosed
EP-3019476-B1 4-MEMBERED RING CARBOXAMIDES USED AS NEMATICIDES SYNGENTA PARTICIPATIONS AG (CH) 2018-01-17 — — EP disclosed
US-9867371-B2 4-membered ring carboxamides used as nematicides SYNGENTA PARTICIPATIONS AG (CH) 2018-01-16 — — US disclosed
US-9867371-B2 4-membered ring carboxamides used as nematicides SYNGENTA PARTICIPATIONS AG (CH) 2018-01-16 — — US disclosed
US-9867371-B2 4-membered ring carboxamides used as nematicides SYNGENTA PARTICIPATIONS AG (CH) 2018-01-16 — — US disclosed
US-20160157485-A1 4-MEMBERED RING CARBOXAMIDES USED AS NEMATICIDES SYNGENTA PARTICIPATIONS AG (CH) 2016-06-09 — — US disclosed
US-20160157485-A1 4-MEMBERED RING CARBOXAMIDES USED AS NEMATICIDES SYNGENTA PARTICIPATIONS AG (CH) 2016-06-09 — — US disclosed
US-20160157485-A1 4-MEMBERED RING CARBOXAMIDES USED AS NEMATICIDES SYNGENTA PARTICIPATIONS AG (CH) 2016-06-09 — — US disclosed
EP-3019476-A1 4-MEMBERED RING CARBOXAMIDES USED AS NEMATICIDES Syngenta Participations AG (CH) 2016-05-18 — — EP disclosed
WO-2015003951-A1 4-MEMBERED RING CARBOXAMIDES USED AS NEMATICIDES SYNGENTA PARTICIPATIONS AG (CH) 2015-01-15 — — WO disclosed
WO-2015003951-A1 4-MEMBERED RING CARBOXAMIDES USED AS NEMATICIDES SYNGENTA PARTICIPATIONS AG (CH) 2015-01-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160157485-A1 4-MEMBERED RING CARBOXAMIDES USED AS NEMATICIDES TUBA3C, DDT, CYCS LMNA 3548/4885GAA 2228/4885PTPRC 3179/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback